KCNH2 and cancer: Based on that, we generated (and patented WO2019/015936) a novel engineered, single chain, bispecific antibody in the format of a diabody (scDb-hERG1-β1), which has been proven to target with high affinity the hERG1/β1 integrin complex in cancer cells (Duranti et al., 2021a; Duranti et al., 2021b).